Drug intelligence / Profile preview

CUSP02

Development stage: Preclinical
Lead developer: OnCusp Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

CUSP02 is a preclinical-stage antibody-drug conjugate (ADC) being developed by OnCusp Therapeutics for the treatment of solid tumors. The drug is part of a pipeline of next-generation ADCs licensed from Multitude Therapeutics. While the specific biological target and payload of CUSP02 have not been publicly disclosed by the company, it is designed to target a tumor-associated antigen to deliver a cytotoxic agent directly to malignant cells. As of 2024, CUSP02 is in the preclinical development phase, following the company's lead asset CUSP06 (a CDH6-targeting ADC) and CUSP01 (a B7-H4-targeting ADC).

Beyond the preview

Go deeper on CUSP02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUSP02.

Explore the full profile